Accelr8 Announces Second Supply Agreement and Expand Original Agreement with Schott
Complete the form below to unlock access to ALL audio articles.
Accelr8 Technology Corporation and SCHOTT Nexterion have announced the signing of a new supply agreement for Nexterion® Slide HS microarray slides using Accelr8’s OptiChem® surface chemistry.
The two companies also expanded a previous supply agreement for Accelr8 to produce Nexterion® Slide H for SCHOTT.
Accelr8 has been manufacturing Slide HS for SCHOTT since October, 2004. Under the new agreement Accelr8 will extend production through December, 2005.
SCHOTT also has a right during 2005 to enter into negotiations for an exclusive manufacturing and distribution license, similar to the Slide H agreement signed November 4, 2004.
Under a prior supply agreement for Slide H, Accelr8 fulfilled the terms as planned, but Nexterion sales exceeded forecast. Therefore Nexterion requested an extension for more products while Nexterion’s own production line ramps up.
According to David Howson, Accelr8’s president, “under the two agreements we estimate that product revenues from Nexterion to Accelr8 will total approximately $150,000 for the remainder of this calendar year.”
The ongoing revenues from Slide H and Slide HS production and licensing occur in parallel with Accelr8’s primary business focus in developing the BACcelr8r™ rapid bacterial analysis system.
“We’re very pleased at the market’s response to Slide H and now initial acceptance of Slide HS by a significant industrial customer,” said Dr. Lutz Wehmeier, SCHOTT Nexterion’s General Manager.
“As part of Nexterion’s comprehensive microarraying product line for DNA as well as protein applications, we value Accelr8’s innovative coating technology in advancing the performance and adaptability of microarray analysis,” Dr. Wehmeier continued.
“Accelr8’s Slide HS technology is important because of the wide familiarity and easily-available commercial kits for binding biotin to the scientist’s target materials, something that all virtually all biomedical scientists know how to do and feel comfortable with,” said Howson. “It’s the easy route – like a biochemical Lego® set – to assay design.”
